This paper is a summary of Blue Matter Breakfast Club meeting #13. Our guest speaker was Olivier Menzel, PhD, MBA, founder and Chairman of the BLACKSWAN Foundation, a Swiss foundation dedicated to R&D for rare disease therapies. The discussion centered around the concept of patient centricity and biopharma companies’ approaches to it.
